Compare Hewlett Packard Enterprise Co (HPE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

HPE stock trades at $63.17, down 10.14% today but remains near recent highs following strong AI infrastructure demand. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $1.11 exceeding expectations by 19%. Technical indicators show a bullish trend with support at $66 and resistance at $72. Recent news highlights a $1.2 billion AI server order from Vultr and upgraded guidance, driving positive sentiment.

HPE presents growth potential from AI infrastructure expansion and strong earnings momentum, though valuation appears elevated with a P/E of 35.47. Key risks include execution challenges in integrating Juniper Networks and competitive pressures in the server market. Analyst consensus targets $70.00 with 47.5% buy ratings, suggesting moderate upside from current levels.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.